Peterson, M.D., M.P.H., Paul Kolm, Ph.D., Zugui Zhang, Ph.D., Lloyd W. Klein, M.D., Richard E. Shaw, Ph.D., Charles McKay, M.D., Laura L. Ritzenthaler, M.B.A., Jeffrey J. Popma, M.D., John C. Messenger, M.D., David M. Shahian, M.D., Frederick L. Grover, M.D., John E. Mayer, M.D., Cynthia M. Shewan, Ph.D., Kirk N. Garratt, M.D., Issam D. Moussa, M.D., George D. Dangas, M.D., and Fred H. Edwards, M.D.: Comparative Performance of Revascularization Strategies The strategies of percutaneous coronary intervention and coronary-artery bypass grafting for revascularization have already been compared in randomized clinical trials.1,2 Although the ultimate way to control for treatment-selection bias is to carry out a randomized trial, such trials have limited power to evaluate subgroups often, and the results might not be generalizable, since individuals and centers tend to be selected highly.Sufferers who undergo surgery, radiation and chemotherapy survive, on average, for approximately one year, with fewer than a quarter of sufferers surviving up to 2 yrs and fewer than 10 % surviving up to five years. The analysis is published on the web in the Journal of the National Cancer Institute. Schwartzbaum and colleagues were granted access to specimens from the Janus Serum Lender in Norway. The bank contains samples collected from citizens throughout their annual medical evaluations or from volunteer blood donors for the last 40 years. Norway also offers registered new cases of tumor in the united states since 1953, and personal identification amounts enable cross-referencing those cases with previously collected bloodstream samples. The researchers analyzed stored samples from 594 individuals who were diagnosed with glioma between 1974 and 2007.